(Q43463193)

23 November 2017

title

Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study (English)

1 reference

23 November 2017

0 references

Jean-francois Bergmann

9

1 reference

23 November 2017

12

1 reference

23 November 2017

S Fournier

1

1 reference

23 November 2017

C Chaffaut

2

1 reference

23 November 2017

A Maillard

3

1 reference

23 November 2017

B Loze

4

1 reference

23 November 2017

C Lascoux

5

1 reference

23 November 2017

L Gérard

6

1 reference

23 November 2017

J Timsit

7

1 reference

23 November 2017

F David

8

1 reference

23 November 2017

E Oksenhendler

10

1 reference

23 November 2017

D Sereni

11

1 reference

23 November 2017

J-M Molina

13

1 reference

23 November 2017

publication date

1 March 2005

1 reference

23 November 2017

1 reference

23 November 2017

volume

6

1 reference

23 November 2017

issue

2

1 reference

23 November 2017

page(s)

129-134

1 reference

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Treatment of antiretroviral-drug-resistant HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

How does expert advice impact genotypic resistance testing in clinical practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Clinically relevant interpretation of genotype for resistance to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

Effectiveness of antiretroviral therapy after protease inhibitor failure: an analytic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2005.00275.X

10.1111/J.1468-1293.2005.00275.X

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference